Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

Le Raison de Résistance: Substandard TB Drugs Found in South Africa

The Times of South Africa recently reported the recall of two TB drugs, manufactured by Pharmascript, after the national health department found them to be substandard. Initial tests at the local WHO laboratory found they did not contain the needed amount of active ingredients, as claimed on the label, and concluded that they "would most likely not have effectively treated 'thousands' of TB patients."

New Round in Tug of War on Nurse Migrants

Somewhere in the cross-oceanic battle over where doctors and nurses are allowed to work, I saw a rather pathetic cartoon: a bunch of little paper dolls with stethoscopes and nurses caps being suspended along a rope traversing half the globe – they were each hanging from their own little noose. Behind this story, real people are indeed victims, and the world is treating them like two-dimensional dolls.

Prevention Failure Redux: Unexpected Tradeoffs in HIV Testing, Prevention and Treatment

Last Monday, CGD posted my working paper entitled, "Prevention Failure: The Ballooning Entitlement Burden of U.S. Global AIDS Treatment Spending and What to Do About It." In response, I've received a number of e-mail comments on various aspects of the paper. A wonder of cyberspace is that I heard from far flung correspondents within hours after the working paper was posted. But the modern technology hasn't overcome the age-old problem of people interpreting an author differently than he intended.

Tearing Down the Barriers: Increasing Access in Emerging Pharmaceutical Markets

Yesterday, the Financial Times reported GlaxoSmithKline's exciting new strategy to expand markets and increase access to medicines in low- and middle-income countries. Through an internal policy known as "tearing down the barriers," the company has established differential pricing schemes within and between India, South Africa and other developing countries, in hopes of shifting to a new low price, high volume business model.

WHO Takes One Step Forward, Two Steps Back on Malaria

Last week, my colleague April Harding blogged about the recent debates on the most effective strategies for increasing coverage of insecticide-treated nets. She took to task Dr. Arata Kochi, head of WHO's malaria program, for promoting free distribution campaigns rather than the multi-prong strategies recommended by his own organization, among others. Dr.

PEPFAR(THER)*: Double the Money, Double the Impact?

In anticipation of the G8 summit and its focus on commitments to international development in Germany next week, President Bush called on Congress a short while ago to double the funding for PEPFAR from 15 to 30 billion dollars when the current plan expires in 2008. The plan for PEPFAR 2, as described in a White House press release is a "continuation and expansion" of the initial PEPFAR program:

Outwitting & Outwaiting ARV Resistance

In the best health news of the year (so far!), a new New England Journal of Medicine study has found that delaying the start of a nevirapine-based antiretroviral therapy by six months can prevent the development of drug resistance in HIV-positive women who took single-dose nevirapine during labor to prevent mother-to-child transmission of the virus.

Changing of the Guard: Hiring the New Global Health Leadership

So how many charismatic, visionary individuals with impeccable technical credentials are there out there in the world of global health? Let's hope there are at least three, and that they are all in the market for new jobs that offer non-stop opportunities for fundraising and political brinksmanship, along with a daily dose of staff malaise.